Previous studies show that the free (unbound) fraction of disopyramide in human serum is drug concentration dependent~ at corresponding serum disopyramide concentrations that are achieved clinically. $^1^{sim}^3^);Moreover$, disopyramide free fraction values vary several fold at any given drug concentration in human serum and tend to decrease as serum cocentrations of alpha-I-acid glycoprotein(AAG) incrase.$^4^)$ A recent $study^5^)$ demonstrates that the free fraction of disopyramide inhuman serum increases almost 2-fold following the addition of $14.4{mu}M/L$ mono-N-dealkyldisopyramide. These studies and others. $^6^),;^7^)$ prompted the present investigation to characterize the protein binding of disopyramide in human serum and solutions of AAG in the presence of mono-N-dealkyldisopyramide (a major metabolite of, disopyramide) and to determine the utility of using commercially available alpha-I-acid glycoprotein for drug protein binding displacement studies. Because many basic and acidic compounds are known to bind to alpha-I-acid $glycoprotein^8^)$ the present study. was performed to determine whteher commercially available AAG would provide a convenient protein source for such binding studies.